Results 121 to 130 of about 6,340 (200)

A perspective study of the possible impact of obeticholic acid against SARS-CoV-2 infection. [PDF]

Inflammopharmacology, 2023
Batiha GE, Al-Kuraishy HM, Al-Gareeb AI, Youssef FS, El-Sherbeni SA, Negm WA.   +5 more
europepmc   +1 more source

Activation of Brown Adipocytes by Farnesoid X Receptor Agonist, Obeticholic Acid-A Potential Novel Therapeutic Avenue in the Management of Obesity. [PDF]

J Clin Med
Dąbrowska AM, Chwil M, Urbańska EM.
europepmc   +1 more source

Anti-Cholestatic Therapy with Obeticholic Acid Improves Short-Term Memory in Bile Duct-Ligated Mice. [PDF]

Am J Pathol, 2023
Gee LMV, Barron-Millar B, Leslie J, Richardson C, Zaki MYW, Luli S, Burgoyne RA, Cameron RIT, Smith GR, Brain JG, Innes B, Jopson L, Dyson JK, McKay KRC, Pechlivanis A, Holmes E, Berlinguer-Palmini R, Victorelli S, Mells GF, Sandford RN, Palmer J, Kirby JA, Kiourtis C, Mokochinski J, Hall Z, Bird TG, Borthwick LA, Morris CM, Hanson PS, Jurk D, Stoll EA, LeBeau FEN, Jones DEJ, Oakley F.   +33 more
europepmc   +1 more source

Transcriptional and Post-Transcriptional Anticholestatic Mechanisms of Obeticholic Acid in Lipopolysaccharide-Induced Cholestasis. [PDF]

Pharmaceutics
Razori MV, Hillotte GL, Martín PL, Barosso IR, Basiglio CL, Ruiz ML, Roma MG.   +6 more
europepmc   +1 more source

Non-Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis. [PDF]

Aliment Pharmacol Ther
Abbas N, Smith R, Lytvyak E, Scaravaglio M, Halliday N, Almahroos A, Eden N, Lloyd-Madden D, Sharma S, Ferguson J, Dyson JK, Thorburn D, Jones D, Montano-Loza AJ, Carbone M, Invernizzi P, Mells G, Culver EL, Trivedi PJ.   +18 more
europepmc   +1 more source

Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid. [PDF]

Liver Int, 2022
De Vincentis A, D'Amato D, Cristoferi L, Gerussi A, Malinverno F, Lleo A, Colapietro F, Marra F, Galli A, Fiorini C, Coco B, Brunetto M, Niro GA, Cotugno R, Saitta C, Cozzolongo R, Losito F, Giannini EG, Labanca S, Marzioni M, Marconi G, Morgando A, Pellicano R, Vanni E, Cazzagon N, Floreani A, Chessa L, Morelli O, Muratori L, Pellicelli A, Pompili M, Ponziani F, Tortora A, Rosina F, Russello M, Cannavò M, Simone L, Storato S, Viganò M, Abenavoli L, D'Antò M, De Gasperi E, Distefano M, Scifo G, Zolfino T, Calvaruso V, Cuccorese G, Palitti VP, Sacco R, Bertino G, Frazzetto E, Alvaro D, Mulinacci G, Palermo A, Scaravaglio M, Terracciani F, Galati G, Ronca V, Zuin M, Claar E, Izzi A, Picardi A, Invernizzi P, Vespasiani-Gentilucci U, Carbone M, on behalf of the Club Epatologi Ospedalieri (CLEO)/Associazione Italiana Gastroenterologi ed Endoscopisti Digestivi Ospedalieri (AIGO) PBC Study Group and, the Italian PBC Registry.   +66 more
europepmc   +1 more source

A Twist in the Tale of a Pig Model of Short-Bowel Syndrome

, 2017
Walters, JRF
core   +1 more source

Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid. [PDF]

BMJ Open
Dunn S, Evans L, Kennedy C, Wafer R, Moody S, Wolstenhulme F, Burton E, Konkoth AB, Fisher H, Chadwick T, Banham A, Hale F, Christie M, Barclay ST, Dyson J, Smith R, Aithal G, Culver E, Aspinall R, Thorburn D, Heneghan M, Hancock HC, Trivedi P, Mells G, Wason J, Jones DEJ.   +25 more
europepmc   +1 more source

Obeticholic Acid and Other Farnesoid-X-Receptor (FXR) Agonists in the Treatment of Liver Disorders. [PDF]

Pharmaceuticals (Basel)
Fiorucci S, Urbani G, Distrutti E, Biagioli M.   +3 more
europepmc   +1 more source

Obeticholic acid and hepatic bile acids: Excellent study faulty conclusion [PDF]

Journal of Hepatology, 2021
openaire   +2 more sources